Phase 3 Trials: FDA Receives End of Phase 2 Documents

On October 12, 2016, the U.S. Food and Drug Administration (FDA) confirmed their receipt of MAPS’ materials in support of our End of Phase 2 meeting with the FDA, scheduled for November 29, 2016. …